DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Recruiting

Conditions: Non Small Cell Lung Cancer
Small Cell Lung Carcinoma
NUT Carcinoma

Interventions: Genetic: Data and Specimen Collection

First Posted Date: 2022-03-03

Last Posted Date: 2024-10-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 500

Registration Number: NCT05265429

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

Not Applicable

Recruiting

Conditions: Acute-graft-versus-host Disease
Chronic Graft-versus-host-disease
Graft Vs Host Disease

Interventions: Behavioral: Attention control
Behavioral: Exercise

First Posted Date: 2022-02-11

Last Posted Date: 2025-02-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT05236062

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

GROW (Glioma Specialists Reaching Out With Support) Support

Not Applicable

Withdrawn

Conditions: Low-grade Glioma
Survivorship
Care Giving Burden

Interventions: Behavioral: GROW (Glioma Specialists Reaching Out With Support) Support Program

First Posted Date: 2022-02-10

Last Posted Date: 2023-01-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT05233215

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Video Education With Result Dependent dIsclosure

Not Applicable

Recruiting

Conditions: Genetic Testing
Ovarian Cancer
Pancreatic Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Renal Cancer
Melanoma
Sarcoma

Interventions: Behavioral: Genetic Counseling
Behavioral: Video Education

First Posted Date: 2022-02-04

Last Posted Date: 2024-11-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1020

Registration Number: NCT05225428

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Phase 2

Recruiting

Conditions: Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Venetoclax
Drug: Zanubrutinib

First Posted Date: 2021-12-23

Last Posted Date: 2025-05-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT05168930

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
South Shore Hospital, South Weymouth, Massachusetts, United States

and more 1 locations

Urologic Lymphadenectomy in AMIGO

Not Applicable

Recruiting

Conditions: Urologic Cancer
Lymph Node Metastasis

Interventions: Device: 3D Slicer
Device: Monaco

First Posted Date: 2021-11-24

Last Posted Date: 2023-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT05132283

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Not Applicable

Recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy
Nerve Pain
Neuropathy
Neuropathy, Painful
Pain
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Chronic Pain

Interventions: Other: Education control
Other: Yoga
Other: Usual care

First Posted Date: 2021-11-16

Last Posted Date: 2024-12-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 268

Registration Number: NCT05121558

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

UPLYFT For Lymphoma Survivors

Not Applicable

Recruiting

Conditions: Lymphoma
Survivorship

Interventions: Other: Interview with Clinicians
Behavioral: Pilot of UPLYFT with Lymphoma Survivors
Other: Field Test of UPLYFT with Lymphoma Survivors

First Posted Date: 2021-10-15

Last Posted Date: 2025-03-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 74

Registration Number: NCT05080166

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Marizomib Central Nervous System (CNS)

Phase 2

Withdrawn

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory

Interventions: Drug: Marizomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2021-09-20

Last Posted Date: 2024-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT05050305

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Venetoclax Plus Inotuzumab for B-ALL

Phase 1

Recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia
B-Cell Lymphoma
ALL

Interventions: Drug: Venetoclax
Drug: Dexamethasone
Drug: Inotuzumab Ozogamicin

First Posted Date: 2021-08-23

Last Posted Date: 2025-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT05016947

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy